804 related articles for article (PubMed ID: 18555033)
41. Nonionic intravenous contrast agent does not cause clinically significant artifacts to 18F-FDG PET/CT in patients with lung cancer.
An YS; Sheen SS; Oh YJ; Hwang SC; Yoon JK
Ann Nucl Med; 2007 Dec; 21(10):585-92. PubMed ID: 18092135
[TBL] [Abstract][Full Text] [Related]
42. Clinical evaluation of PET image reconstruction using a spatial resolution model.
Andersen FL; Klausen TL; Loft A; Beyer T; Holm S
Eur J Radiol; 2013 May; 82(5):862-9. PubMed ID: 23254158
[TBL] [Abstract][Full Text] [Related]
43. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.
Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S
Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328
[TBL] [Abstract][Full Text] [Related]
44. Dual time point 2-[18F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis.
Sahlmann CO; Siefker U; Lehmann K; Meller J
Nucl Med Commun; 2004 Aug; 25(8):819-23. PubMed ID: 15266177
[TBL] [Abstract][Full Text] [Related]
45. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
46. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?
Kunikowska J; Matyskiel R; Toutounchi S; Grabowska-Derlatka L; Koperski L; Królicki L
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709
[TBL] [Abstract][Full Text] [Related]
47. Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results.
Christlieb SB; Strandholdt CN; Olsen BB; Mylam KJ; Larsen TS; Nielsen AL; Rohde M; Gerke O; Olsen KE; Møller MB; Kristensen BW; Abildgaard N; Alavi A; Høilund-Carlsen PF
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1824-36. PubMed ID: 27102266
[TBL] [Abstract][Full Text] [Related]
48. FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours.
Nakajo M; Jinguji M; Fukukura Y; Kajiya Y; Tani A; Nakajo M; Nakabeppu Y; Arimura H; Nishio Y; Nakamura F; Yoshiura T
Eur Radiol; 2015 Dec; 25(12):3696-705. PubMed ID: 25925356
[TBL] [Abstract][Full Text] [Related]
49. Differential diagnosis of pulmonary lesions by parametric imaging in (18)F-FDG PET/CT dynamic multi-bed scanning.
Wang Q; Wang RF; Zhang J; Zhou Y
J BUON; 2013; 18(4):928-34. PubMed ID: 24344019
[TBL] [Abstract][Full Text] [Related]
50. Dual-time-point F-18 FDG PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer.
Shinya T; Rai K; Okumura Y; Fujiwara K; Matsuo K; Yonei T; Sato T; Watanabe K; Kawai H; Sato S; Kanazawa S
Clin Nucl Med; 2009 Apr; 34(4):216-21. PubMed ID: 19300050
[TBL] [Abstract][Full Text] [Related]
51. Predictive value of F-18 FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patients.
Kim BS; Kim IJ; Kim SJ; Pak K; Kim K
Onkologie; 2011; 34(6):298-303. PubMed ID: 21625182
[TBL] [Abstract][Full Text] [Related]
52. Diagnostic accuracy of (18)F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T.
Magometschnigg HF; Baltzer PA; Fueger B; Helbich TH; Karanikas G; Dubsky P; Rudas M; Weber M; Pinker K
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1656-1665. PubMed ID: 26121928
[TBL] [Abstract][Full Text] [Related]
53. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease.
Choi EK; Yoo IeR; Kim SH; O JH; Choi WH; Na SJ; Park SY
Clin Nucl Med; 2013 Mar; 38(3):e106-11. PubMed ID: 23354026
[TBL] [Abstract][Full Text] [Related]
54. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes.
Mavi A; Urhan M; Yu JQ; Zhuang H; Houseni M; Cermik TF; Thiruvenkatasamy D; Czerniecki B; Schnall M; Alavi A
J Nucl Med; 2006 Sep; 47(9):1440-6. PubMed ID: 16954551
[TBL] [Abstract][Full Text] [Related]
55. Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions.
Imbriaco M; Caprio MG; Limite G; Pace L; De Falco T; Capuano E; Salvatore M
AJR Am J Roentgenol; 2008 Nov; 191(5):1323-30. PubMed ID: 18941064
[TBL] [Abstract][Full Text] [Related]
56. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
[TBL] [Abstract][Full Text] [Related]
57. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT.
Bogsrud TV; Karantanis D; Nathan MA; Mullan BP; Wiseman GA; Collins DA; Kasperbauer JL; Strome SE; Reading CC; Hay ID; Lowe VJ
Nucl Med Commun; 2007 May; 28(5):373-81. PubMed ID: 17414887
[TBL] [Abstract][Full Text] [Related]
58. Value of ¹⁸F-FDG PET/CT in the diagnosis of primary gastric cancer via stomach distension.
Ma Q; Xin J; Zhao Z; Guo Q; Yu S; Xu W; Liu C; Zhai W
Eur J Radiol; 2013 Jun; 82(6):e302-6. PubMed ID: 23434453
[TBL] [Abstract][Full Text] [Related]
59. [Differentiation of malignant and benign superficial lymph nodes by dual time point 18F-FDG PET].
Su MG; Fan QP; Tian Y; Li FL; Yang XC; Li L; Fan CZ; Tian R
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):517-20. PubMed ID: 19627018
[TBL] [Abstract][Full Text] [Related]
60. Usefulness of dual-phase 18F-FDG PET/CT for diagnosing small pancreatic tumors.
Kawada N; Uehara H; Hosoki T; Takami M; Shiroeda H; Arisawa T; Tomita Y
Pancreas; 2015 May; 44(4):655-9. PubMed ID: 25815646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
